NEWSROOM
Press Releases by Agendia
News
Press Releases
Agendia Announces Presentation of Data Highlighting Symphony Suite of Genomic tests (MammaPrint, BluePrint, and TargetPrint) at San Antonio Breast Cancer Symposium
Ten Scientific Posters Document Study Results on Second-Generation Symphony Suite, Containing Multi-Gene Signatures to Provide Molecular Subtyping IRVINE, CA and AMSTERDAM, THE NETHERLANDS, December 9, 2013 – New breast cancer research incorporating the SymphonyTM suite Read More
Multiple International Breast Cancer Guidelines Confirm Use of Agendia Tests for Prognostic, Predictive Information in Cancer Treatment Decisions
Important Role of Molecular Subtyping in Determining the Need for Chemotherapy also Cited IRVINE, CA, and AMSTERDAM, THE NETHERLANDS, September 9, 2013 – Agendia, a leader in molecular cancer diagnostics, today announced that multiple established Read More
Researchers Identify Splice Variant of Breast Cancer Gene that Can Mask Risk of Recurrence
‘High Risk’ Patients with Unusual Hormone Receptors May Be Undertreated IRVINE, CA and AMSTERDAM, THE NETHERLANDS, August 27, 2013 – Agendia, a leader in molecular cancer diagnostics, announced today that researchers have identified a subset Read More
Molecular Subtyping Can Help Determine Prognosis and Chemotherapy Benefit in Colorectal Cancer Patients
CHICAGO – Molecular subtyping can help predict outcomes and chemotherapy benefit in patients with colorectal cancer, according to a presentation at the annual conference of the American Society of Clinical Oncology (ASCO). This scientific poster Read More
Ground-breaking Research Identifies Molecular Subtyping as a Key to Determining Prognosis and Benefit of Chemotherapy for Breast and Colorectal Cancers
IRVINE, CA, May 31, 2013 – Agendia, a world leader in molecular cancer diagnostics, today announced that results from five studies focused on breast, colon and colorectal cancer will be presented at the upcoming American Read More
Agendia Reports More Than 20,000 MammaPrint Breast Cancer Recurrence Results
IRVINE, CA, May 2, 2013 – Agendia, a world leader in molecular cancer diagnostics, today announced that it has reported more than 20,000 MammaPrint breast cancer results, including approximately 6,000 in 2012 alone. The MammaPrint Read More
Study shows half of early-stage breast cancer patients may be able to avoid chemotherapy
Agendia Announces Launch of ColoPrint for Colon Cancer Prognosis and Prediction
